Stay updated on Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.

Latest updates to the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe ClinicalTrials.gov page now displays the study record for a cabozantinib-based treatment strategy for refractory multiple myeloma, including its terminated status and detailed trial information, where it previously showed a 403 error.SummaryDifference61%

- Check17 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check24 days agoChange DetectedA banner announces NIH’s website transition and says that “Super Intelligence” may be used in place of “Artificial Intelligence” across NIH content, with a link to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe footer’s site revision changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check38 days agoChange DetectedThe site's footer revision identifier changed from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now displays a 403 Forbidden message, indicating that access to the study record is blocked. The previous study content appears to be unavailable due to restricted access.SummaryDifference21%

Stay in the know with updates to Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.